My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
RES-2022-168
>
Meetings
>
2022
>
09. September
>
2022-09-06 10:00 AM - Commissioners' Agenda
>
RES-2022-168
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/13/2022 11:54:56 AM
Creation date
9/13/2022 11:53:49 AM
Metadata
Fields
Template:
Meeting
Date
9/6/2022
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve a Resolution Authorizing the Chair's Signature on a Opioid Litigation Allocation Agreement
Order
3
Placement
Consent Agenda
Row ID
93293
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
107
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
FINAL AGREEMENT 3.25.22 <br />l. Increase the number of prescribers using PDMPs; <br />2.Improve point-of-care decision-making by increasing the quantity, quality, <br />or format of data available to prescribers using PDMPs, by improving the <br />interface that prescribers use to access PDMP data, or both; or <br />Enable states to use PDMP data in support of surveillance or intervention <br />strategies, including MAT referrals and follow-up for individuals <br />identified within PDMP data as likely to experience OUD in a manner that <br />complies with all relevant privacy and security laws and rules. <br />Ensuring PDMPs incorporate available overdose/naloxone deployment data, <br />including the United States Department of Transportation's Emergency Medical <br />Technician overdose database in a manner that complies with all relevant privacy <br />and security laws and rules. <br />Increasing electronic prescribing to prevent diversion or forgery. <br />Educating dispensers on appropriate opioid dispensing. <br />G. PREVENT MISUSE OF OPIOIDS <br />Support efforts to discourage or prevent misuse of opioids through evidence-based or <br />evidence-informed programs or strategies that may include, but are not limited to, the <br />following: <br />Funding media campaigns to prevent opioid misuse <br />Corrective advertising or affirmative public education campaigns based on <br />evidence. <br />Public education relating to drug disposal. <br />Drug take-back disposal or destruction programs. <br />Funding community anti-drug coalitions that engage in drug prevention efforts. <br />Supporting community coalitions in implementing evidence-informed prevention, <br />such as reduced social access and physical access, stigma reduction-including <br />staffing, educational campaigns, support for people in treatment or recovery, or <br />training of coalitions in evidence-informed implementation, including the <br />Strategic Prevention Framework developed by the U.S. Substance Abuse and <br />Mental Health Services Administration (" SAMHSA"). <br />Engaging non-profits and faith-based communities as systems to support <br />prevention. <br />J <br />6. <br />7 <br />8 <br />1 <br />2 <br />aJ <br />4 <br />5 <br />6 <br />l <br />E-l1
The URL can be used to link to this page
Your browser does not support the video tag.